Rockefeller's Redesigned CD40 Antibody Eliminates Metastatic Cancers in Phase 1 Trial, Sparking Nearly 200-Patient Expansion
An Fc-engineered CD40 agonist injected into a single tumor triggered systemic immune responses that eliminated cancer across the body in two patients, with expanded trials now under way at Memorial Sloan Kettering and Duke.